Ribavirin treatment in murine autoimmune disease
β Scribed by Lynell W. Klassen; Gary W. Williams; James L. Reinertsen; N. Lynn Gerber; Alfred D. Steinberg
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 786 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
he in vivo local delivery of regulatory cytokines made possible by gene therapy is becoming an exciting approach for treating common disorders such as cancer and viral infections I. Recently, gene therapy strategies have been applied to the treatment of autoimmune diseases. Cells targeted for autoim
## Abstract No Abtract
Experimental autoimmune thyroid disease (EAT) can be induced experimentally in mice following immunization with mouse thyroglobulin (mTg) and the adjuvants lipopolysaccharide (LPS) or complete Freund's adjuvant (CFA). EAT can also be transferred to naive recipients by CD4 + T cells from mTg-primed m
The elimination of autoreactive T cells in the thymus involves the process of programmed cell death. Animal model studies, using the lpr and gld strains of mice, have identified FAS receptor (FAS) and FAS ligand (FAS-L) as important components of this mechanism. Whether FAS and FAS-L are also implic
## Abstract Autoimmune diseases are characterized by the loss of tolerance toward selfβantigens and the induction of destructive immune responses leading to tissue damage. Most patients with autoimmune diseases are treated with immunosuppressive drugs that suppress the immune response in a nonβspec